359 related articles for article (PubMed ID: 33569666)
1. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
[No Abstract] [Full Text] [Related]
2. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
3. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
4. Biologic Therapy for Ulcerative Colitis.
Bhattacharya A; Osterman MT
Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
6. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
Restellini S; Khanna R; Afif W
Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
[TBL] [Abstract][Full Text] [Related]
10. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
[TBL] [Abstract][Full Text] [Related]
11. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
12. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
13. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
14. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
[TBL] [Abstract][Full Text] [Related]
15. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
Conrad MA; Kelsen JR
Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
[TBL] [Abstract][Full Text] [Related]
17. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Ko Y; Paramsothy S; Yau Y; Leong RW
Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis.
Veyrard P; Pellet G; Laharie D; Nachury M; Juillerat P; Roblin X
Clin Gastroenterol Hepatol; 2023 May; 21(5):1354-1355.e2. PubMed ID: 35307594
[TBL] [Abstract][Full Text] [Related]
19. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review.
Gisbert JP; García MJ; Chaparro M
J Crohns Colitis; 2023 Jun; 17(6):972-994. PubMed ID: 36652279
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis.
Patel PV; Zhang A; Bhasuran B; Ravindranath VG; Heyman MB; Verstraete SG; Butte AJ; Rosen MJ; Rudrapatna VA;
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1126-1134. PubMed ID: 38482890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]